Abstract
Background Despite the high prevalence of disabling post-stroke cognitive sequalae, these impairments are often underdiagnosed and rarely monitored longitudinally. Provision of unsupervised remote online cognitive technology would provide a scalable solution to this problem. However, despite recent advances, such technology is currently lacking, with existing tools either not meeting the scalability challenge or not optimised for specific applications in post-stroke cognitive impairment. To address this gap, we designed and developed a comprehensive online battery highly optimised for detecting cognitive impairments in stroke survivors.
Method The technology is optimised to allow both diagnosis and monitoring of post-stroke deficits, and for remote unsupervised administration. Participants performed 22 computerised tasks, and answered neuropsychiatric questionnaires and patient reported outcomes. 90 stroke survivors (Mean age = 62.1 years; 68% and 32% in the acute and subacute/chronic phase after stroke respectively) and over 6,000 age-matched healthy older adults were recruited. Patient outcome measures were derived from Bayesian Regression modelling of the large normative sample and validated against standard clinical scales.
Results Our online technology has greater sensitivity to post-stroke cognitive impairment than pen-and-paper tests such as the MOCA (mean sensitivity 81.75% and 52.25% respectively, P<0.001). Further, our outcomes show a stronger correlation with post-stroke quality of life (r(78)=0.51, R2=0.26, P<0.001) when compared to MOCA, which only explains half of this variance (r(78)=0.38, R2=0.14, P< 0.001). An additional set of experiments confirm that the online tasks yield highly reliable outcomes, with consistent performance observed across supervised versus unsupervised settings, and minimal learning effects across multiple timepoints.
Conclusion The current online cognitive monitoring technology is feasible, sensitive, and reliable when assessing patients with stroke. The technology offers an economical and scalable method for assessing post-stroke cognition in the clinical setting and sensitively monitoring cognitive outcomes in clinical trials for stroke.
Competing Interest Statement
AH is co-director and owner of H2CD Ltd, and owner and director of Future Cognition Ltd, which support online studies and develop custom cognitive assessment software respectively. PH is co-director and owner of H2CD Ltd and reports personal fees from H2CD Ltd, outside the submitted work.
Clinical Protocols
https://www.medrxiv.org/content/10.1101/2023.08.23.23294469v1
Funding Statement
This research is funded by the UK Medical Research Council (MR/T001402/1). Infrastructure support was provided by the NIHR Imperial Biomedical Research Centre and the NIHR Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. DCG is funded by Imperial College London. SB is funded by Impact Acceleration Award (PSP415 EPSRC IAA, and PSP518 MRC IAA). AH is supported by the Biomedical Research Centre at Imperial College London. V.G. is supported by the Medical Research Council (MR/W00710X/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been ethically approved by South West - Frenchay Research Ethics Committee (IRAS 299333), and authorized by the UK's Health Research Authority (Registered under NCT05885295; REC:21/SW/0124).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
A subset of the datasets used can be made available on reasonable request from the corresponding author and upon institutional regulatory approval.
